Focal Points 2012 Module: Biologic Response Modifiers in Uveitis

Learn about a new line of treatment for uveitis – the third leading cause of blindness in developed nations. While corticosteroids and other corticosteroid-sparing agents have been widely used in management of noninfectious uveitis, this Focal Points module focuses on a newer line of therapy termed biologic agents. Biologic agents have shown efficacy as primary therapy for uveitis or as secondary corticosteroid-sparing agents. Biologic agents are increasingly being used not only for uveitis, but also for treatment of other inflammatory ocular diseases. With peak onset for uveitis occurring between 20 and 40 years of age among working individuals, it is important to know the latest about treating this significant public health concern.

Upon completion of this Focal Points module, you should be able to:

• Demonstrate understanding of the current range of biologic agents available for the treatment of uveitis and ocular inflammatory disease.
• Describe the side effects associated with the biologic agents.
• Be aware of the newer biologic agents on the horizon that may be useful in clinical practice for the treatment of inflammatory eye diseases.

Focal Points modules are practical, hands-on discussions of the clinical issues you face daily. Each module delivers high-quality, trusted ophthalmic information written and reviewed by leading experts. Subscribe to Focal Points and receive 12 modules a year in the print or interactive online format.

CME Credit: The American Academy of Ophthalmology designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Once you have completed this Focal Points module, please visit CME Central to review or claim your CME. After purchasing this product, you may access it at www.aao.org/myonlineproducts.